Quizalize logo
placeholder image to represent content

MOUNJARO QUIZ 2

Quiz by Christina

Feel free to use or edit a copy

includes Teacher and Student dashboards

Measure skills
from any curriculum

Tag the questions with any skills you have. Your dashboard will track each student's mastery of each skill.

With a free account, teachers can
  • edit the questions
  • save a copy for later
  • start a class game
  • automatically assign follow-up activities based on students’ scores
  • assign as homework
  • share a link with colleagues
  • print as a bubble sheet

Our brand new solo games combine with your quiz, on the same screen

Correct quiz answers unlock more play!

New Quizalize solo game modes
30 questions
Show answers
  • Q1

    What is the definition of obesity according to the World Health Organization?

    A disease caused by an unhealthy lifestyle.

    A mental health disorder linked to food choices

    A condition characterized by excessive body weight

    A multifactorial disease associated with excessive adiposity.

    60s
  • Q2

    Which of the following best describes the role of GIP in Mounjaro’s mechanism of action?

    a) Enhances insulin sensitivity in peripheral tissues

    b) Inhibits appetite through central nervous system pathways

    d) All except c

    c) Increases glucagon secretion

    d) Promotes insulin secretion from pancreatic beta cells

    e) All the above

    60s
  • Q3

    Type 2 DM is characterized by three pathophysiologic abnormalities

    Impaired insulin secretion

    Increased hepatic glucose production

    Peripheral insulin resistance

    All the above

    60s
  • Q4

    Incretin effect was defined as a phenomenon in which IV administered glucose leads to a greater release of insulin than does Oral glucose administration.

    False

    True

    60s
  • Q5

    According to ADA guidelines, the following is/are recommended in patients with HF

    GLP-1 Receptor agonists

    SGLT-2 inhibitors

    All the above

    DPP-4 inhibitors

    60s
  • Q6

    According to ADA guidelines, the following is/are recommended in patients with Chronic Kidney Disease

    e) a & b

    b) GLP-1 Receptor agonists

    c) Metformin

    d) All the above

    a) SGLT-2 inhibitors

    60s
  • Q7

    The role of GLP-1 in T2D and Obesity management

    Users link answers
    Linking
    120s
  • Q8

    In SURPASS-3, The Liver Fat content decreased by

    51%

    47%

    52%

    46%

    60s
  • Q9

    The composite endpoint in SURPASS-2 was:

    All the above 

    a) HbA1c ≤6.5% 

    d) Nearly 2 times as many patients vs semaglutide

    1 mg achieve a composite endpoint

    c)Weight reduction ≥10%

    b) No significant or severe hypoglycemia

    All except d

    60s
  • Q10

    The SURPASS trial that included patients with increased CV risk

    SURPASS-4

    SURPASS 2

    SURPASS-5

    SURPASS-3

    60s
  • Q11

    All the following has low risk of Hypoglycemia except:

    a) Sulfonylurea

    All the above

    d) DPP-4 inhibitors

    c) GLP-1 receptor agonist

    All except a

    b) SGLT2 inhibitors

    60s
  • Q12

    The Primary endpoint was to test the non-inferiority of Tirzepatide doses in the following trials

    a) SURPASS-1, b) SURPASS-2, c) SURPASS-3, d)SURPASS-4, e)SURPASS-5

    c & d & e

    a & e

    a & b

    c & d & e

    b & c & d

    60s
  • Q13

    In SURPASS-2, the HbA1c reductions of MOUNJARO compared with Semaglutide 1mg was up to

    2.6%

    2.1%

    2.46%

    2.58

    60s
  • Q14

    MOUNJARO 15 mg achieved ...........the weight loss vs. Semaglutide 1 mg

    3 times 

    2 times

    30s
  • Q15

    Which hormone is produced by the stomach and increases hunger?

    Ghrelin

    Cortisol

    Leptin

    Insulin

    30s

Teachers give this quiz to your class